Post on 23-Sep-2020
transcript
Sample to Insight
Investor presentationQ1 2018
1Investor presentation Q1 2018
Sample to Insight
Disclaimer
Investor presentation Q1 2018 2
Safe Harbor Statement: This presentation contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be forward lookingstatements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements are based oncurrent expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from our own expectations and projections.Some of the factors that could cause actual results to differ include, but are not limited, to the following: general industry conditions and competition; risks associated with managing growth and internationaloperations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, and the commercialdevelopment of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition;rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including factors such as general economic conditions, the level and timing of customers' funding, budgets andother factors); our ability to obtain regulatory approval of our products; technological advances of our competitors and related legal disputes; difficulties in successfully adapting QIAGEN's products tointegrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitor products; market acceptance ofQIAGEN's new products and the integration of acquired technologies and businesses. For further information, please refer to “Risk Factors” section of reports that QIAGEN has filed with, or furnished to, theU.S. Securities and Exchange Commission (SEC). We undertake no obligation, and do not intend, to update these forward-looking statements as a result of new information or future events or developmentsunless and to the extent required by law.
Regulation G: QIAGEN reports adjusted results, as well as results on a constant exchange rate (CER) basis, and other non-U.S. GAAP figures (generally accepted accounting principles), to provideadditional insight on performance. In this presentation, adjusted results include adjusted net sales, adjusted operating expenses, adjusted EBITDA, adjusted diluted EPS and free cash flow. Adjusted resultsare non-GAAP financial measures QIAGEN believes should be considered in addition to reported results prepared in accordance with GAAP, but should not be considered as a substitute. QIAGEN believescertain items should be excluded from adjusted results when they are outside of its ongoing core operations, vary significantly from period to period, or affect the comparability of results with its competitorsand its own prior periods. Please see the Appendix provided in this presentation “Reconciliation of Non-GAAP to GAAP Measures” for reconciliations of historical non-GAAP measures to comparable GAAPmeasures and the definitions of terms used in the presentation. QIAGEN does not reconcile forward-looking non-GAAP financial measures to the corresponding GAAP measures due to the high variabilityand difficulty in making accurate forecasts and projections that are impacted by future decisions and actions. Accordingly, reconciliations of these forward-looking non-GAAP financial measures to thecorresponding GAAP measures are not available without unreasonable effort. However, the actual amounts of these excluded items will have a significant impact on QIAGEN’s GAAP results.
GeneReader NGS System: The QIAGEN GeneReader® NGS System is intended for Research Use Only. This product is not intended for the diagnosis, prevention or treatment of a disease. QIAGENClinical Insight® is an evidence-based decision support software intended as an aid in the interpretation of variants observed in genomic sequencing data. The software evaluates genomic variants in thecontext of published biomedical literature, professional association guidelines, publicly available databases and annotations, drug labels and clinical-trials. Based on this evaluation, the software proposes aclassification and bibliographic references to aid in the interpretation of observed variants. The software is not intended as a primary diagnostic tool by physicians or to be used as a substitute for professionalhealthcare advice. Each laboratory is responsible for ensuring compliance with applicable international, national and local clinical laboratory regulations and other accreditation requirements.
Sample to Insight
Agenda
3
Appendix
Portfolio review
Full-year 2017 results
Introducing QIAGEN
Investor presentation Q1 2018
Sample to Insight
Investor presentation Q1 2018
THE BUILDING BLOCKS OF LIFE:
DNA AND RNA
4
The molecular revolution is gaining momentum – importance of valuable insights
Sample to Insight
Investor presentation Q1 2018 5
How can we
achieve scientific
breakthroughs
even faster?
How can we
develop better
and safer drugs?
How can we
improve
public safety?
How can we
further improve
outcomes for
patients?
ADDRESSING THE WORLD’S
MOST PRESSING CHALLENGES
Expanding the range of customers who can benefit from molecular solutions
Sample to Insight
Investor presentation Q1 2018 6
CUSTOMERS RELY ON QIAGEN
TO MASTER THESE CHALLENGES
Sample Technologies Assay Technologies
Bioinformatics Automation systems
SAMPLE TO INSIGHT SOLUTIONSBIOLOGICAL
SAMPLE
VALUABLE
MOLECULAR INSIGHTS
Faster Better More efficiently
#1
#1
Top 3
Top 5
QIAGEN: World leader in molecular testing solutions that enable valuable insights
Sample to Insight
Investor presentation Q1 2018 7
Sample Technologies Assay Technologies
Bioinformatics Automation systems
SAMPLE TO INSIGHT SOLUTIONS
#1
Top 3
Top 5
#1
BIOLOGICAL
SAMPLE
VALUABLE
MOLECULAR INSIGHTS
QIAGEN: World leader in molecular testing solutions that enable valuable insights
Sample to Insight
8
Facts and figures
2017 sales ~$1.42 billion
Customers >500,000
Global reach >35 countries
Employees ~4,700
Share listings Frankfurt / NYSE
Headquarters Netherlands
QIAGEN at a glance
Leader in molecular testing solutions
True hybrid covering continuum from
Life Sciences to Molecular Diagnostics
~87%
~13%
Instruments and automation systems
Consumables (incl. bioinformatics)
World leader in molecular testing, transforming biological samples into valuable insights
Scientific breakthroughs
Academia
~23%
Pharma
~19%
Better and safer drugs
Applied Testing
~10%
Secure and protect
Molecular Diagnostics
~48%
Better healthcare
Investor presentation Q1 2018
Sample to Insight
2009 2011 2013 2015 2016 2017 2020
Investor presentation Q1 2018 9
QIAGEN delivering value and improving sales, progress as U.S. HPV headwinds fade away
Sales by customer class(As % of annual net sales)
2009 2011 2013 2015 2016 2017 2020
$1.01 bn $1.17 bn $1.30 bn
26%
26%
23%
21%20%
19%
6%7%
8%
22% 20% 16%
25% 27%34%
$1.28 bn
22%
20%
9%
3%
46%
$1.34 bn
22%
19%
9%
3%
47%
23%
19%
10%
2%
46% MDx core portfolio
U.S. HPV
Applied Testing
Pharma
Academia
Total sales $1.42 bn
Full-year 2017: +7% CER net sales growth, excluding business portfolio changes
Sample to Insight
2009 2017
Investor presentation Q1 2018 10
QIAGEN going through transformation to focus on attractive growth opportunities
Sales by customer class(As % of annual net sales)
MDx core portfolio
U.S. HPV
Applied Testing
Pharma
Academia
CAGR – Compound annual growth rate
100% 100%
26%
21%
6%
22%
25%
23%
19%
10%2%
46%
2020
55%
45%
2016-2020 target:
~+7-9% CER CAGR
Sample to Insight
Investor presentation Q1 2018 11
2020 ambitions
~+7-9% CER
CAGR
$1,338 m
+6% CER
2020
target
2016
$1.11
$340 m
≥12% CER
CAGR ~$600 m
2020 ambitions: Strong growth in sales, adjusted EPS and cash flow
Net sales Adjusted EPS Operating cash flow
2020
target
2016 2020
target
2016
Sample to Insight
Investor presentation Q1 2018 12
Supporting our business expansion while increasing returns to shareholders
Targeted M&A / licensing
Continuing our strategy
Novel technologies
Molecular test content
Geographic expansion
Increase returns
Returned $300 million in 2017
New commitment in 2018 to return $200 million via repurchases
Reinvest for organic growth
Capture more value from our Sample to Insight portfolio
New products
Geographic expansion
Disciplined
capital allocation
Sample to Insight
Investor presentation Q1 2018 13
Mu
ltip
le d
rive
rs
Greater
value
creation
+ Maximize sales growth
+ Deliver operating leverage
+ Optimize balance sheet
= Adjusted EPS growth and high returns
+ Strong governance and top talent
Committed to higher returns and greater value creation as differentiated leader
Sample to Insight
Agenda
14
Appendix
Portfolio review
Full-year 2017 results
Introducing QIAGEN
Investor presentation Q1 2018
Sample to Insight
Life
Sciences
Molecular
Diagnostics
QuantiFERON ✓
Next-generation sequencing ✓ ✓
Personalized Healthcare ✓ ✓
QIAsymphony ✓ ✓
Differentiated Technologies
Applications including:
■ Liquid biopsy
■ Microbiome
■ Single-cell research
■ Epigenetics
✓ ✓
15
Key highlight areas: QIAGEN’s Sample to Insight portfolio
Powered by
QIAGEN Bioinformatics
Growth opportunities around Sample to Insight portfolio
Investor presentation Q1 2018
Sample to Insight
QuantiFERON
Investor presentation Q1 2018 16
Global gold standard for blood-based TB testing and key supporter of global fight to eliminate TB
2017 highlights
24% full-year sales growth
U.S. launch of 4th-gen QuantiFERON-TB Gold Plus
New clinical data confirm patient stratification value
of new CD8+ technology
Won tenders in South Korea and Middle East
Resolved U.S. patent litigation
2018 catalysts
QIAGEN-DiaSorin partnership providing powerful
workflow automation option (Europe in Q3 2018)
Japan launch of 4th-gen QuantiFERON-TB Gold Plus
Guideline expansion to drive conversion of
~65 million annual TB test addressable market
2020 goal to exceed $300 million of annual sales
Sample to Insight
QuantiFERON
17
BCG – Bacillus Calmette-Guerin vaccine NTM – Non-tuberculosis mycobacteria IGRA – Interferon-gamma release assay
(1) Not available in all markets
Can be fully automated
Highly specific
Results with one patient visit
No inter-reader variability
Electronic results
Quality-assured laboratory test(1)
QuantiFERON-TB (QFT)
Manual placement, reading, data entry
Affected by BCG vaccine and NTM
Two patient visits required
Significant inter-reader variability
Poor surveillance tool
Often no quality control after training
Tuberculin skin test (TST)
Investor presentation Q1 2018
QuantiFERON-TB: Leading IGRA with significant clinical and workflow benefits
Sample to Insight
QuantiFERON
Investor presentation Q1 2018 18
Immune Monitoring: Expand QuantiFERON benefits
Japan Market: ~7 million skin tests Launch QFT-Plus in 2017 Develop commercial partner network
2020 target: >$300 million sales
Intensify commercial activities in strategic markets
Automation upgrades to improve workflow
Continue menu expansion
Europe / Middle East / Africa Market: ~5 million skin tests Dubai hub to expand
regional activities
Latin America Market: ~8 million skin tests Support public health
guidelines (WHO)
North America Market: ~15 million skin tests FDA approval of QFT-Plus in 2017 Commercial power: Adding reps
Asia-Pacific Market: ~15 million skin tests Highest TB burden region Go direct in attractive markets Influence guidelines
China Market: ~15 million skin tests
(available to QFT) Build networks and drive clinical demand Support LTBI guidelines
Total
convertible skin
test market:
~65 million
tests annually
QuantiFERON-TB: Drive commercial success through targeted global actions
Sample to Insight
Next-generation sequencing
Investor presentation Q1 2018 19
Strategic provider of differentiated solutions across all segments of fast-growing NGS market
2017 highlights
Exceeded $115 million CER in annual sales
Rapid expansion of “digital NGS” QIAseq multiplex
gene panel portfolio for use on any NGS sequencer
GeneReader NGS System: Expanding global reach with
China MAQGEN joint venture, new customized panels
2018 catalysts
Targeting over $140 million CER in annual sales
New Enterprise Genomics Service to address
demand for customized gene panels for any sequencer
Strong growth in GeneReader placements and usage:
enhancements with new chemistry and gene panels
CER – Constant exchange rates
Sample to Insight
GeneReader NGS System
Investor presentation Q1 2018 20
Actionable
insights
Expertise
and service
First complete
NGS workflow
Flexibility to
fit needs
Reliable resultsEase of use Unique automation Data interpretation
QIAcube®
Predictable
costs
1
The world’s first complete Sample to Insight NGS solution for actionable results
GeneRead QIAcube® GeneReader™ Bioinformatics portfolio
2 3 4 5
Sample to Insight
GeneReader NGS System
QIAGEN Target customer requirements Comp. I Comp. T
Actionability(1) 100% 100% 70% 80%
Integration of bioinformatics 100% 70% 80%
Strength of Knowledge Base, # publications >30k Third party >1k
Actionable variants detected in panel >700 500 600
Analytical performance 100% 100% 70% 80%
Accuracy (Q-score)>35 to >60
UMI 30 25
Read length (base pairs) 150 2x300 600
Integration and in-process controls 100% 70% 80%
Throughput range of tumor panel(2) 200-3,000 250-1,500 300-1,000 ≥1,000
Data output (gigabases) 6 15 15
Sample to result turnaround time (days) 5 4 3
Time to go live (months) 1 3-9 3-9
Investor presentation Q1 2018 21
(1) Based on 2 use case scenarios: a) QIAact AIT vs. AmpliSeq Hotspot vs. Tumor 15; b) QIAact Lung vs. Oncomine Lung vs. Tumor 15
(2) Based on price per sample analysis incl. consumables, hardware and software (no service) for use-case a): QIAact AIT vs. AmpliSeq Hotspot vs. Tumor 15
UMI – Unique Molecular Indices
Optimum
Optimum
Minimum
Minimum Optimum
Minimum
Meeting and exceeding target requirements with strong competitive position
Sample to Insight
0 250 500 750 1,000 1,500 2,000 2,500
GeneReader NGS System
Investor presentation Q1 2018 22
GeneReader targeting a distinct and highly attractive market segment
Clinical research market throughput(1)
Applications covered by GeneReader NGS System(2)Throughput per small benchtop system (<15GB)
Share of
marketPanels
Large
panels
WES /
WGS
Research 80% 20% 40% 40%
Clinical research
and diagnostics20% 70% 20% 10%
Research Clinical researchand diagnostics
No. of la
bora
tories
Panels
Samples per year
Low
~$40
>$150
Larg
e
panels
WE
SW
GS
Average
throughput
(1) Including pathology market (2) Based on price per sample analysis incl. consumables, hardware and software (no service) for use-case:
QIAact AIT vs. AmpliSeq Hotspot vs. Tumor 15 WES – Whole exome sequencing WGS – Whole genome sequencing
NGS market by application
(In $ thousands per year)
Research Clinical research
and diagnostics
Majority of use is in the mid to low
throughput
GeneReader addresses throughput needs of panel market very well
Higher consumable pull-through for
clinical labs
Comp. T
Comp. I
Throughput
Medium High
GeneReader
Sample to Insight
Personalized Healthcare
Investor presentation Q1 2018 23
Enabling valuable insights to help guide treatment decisions
CDx – Companion diagnostics
2017 highlights
2018 catalysts
Exceeded 25 master collaboration agreements
with leading pharma and biotech companies
First-ever NGS-based immuno-oncology CDx
consortium with Bristol-Myers Squibb
First FDA-cleared JAK2 test for blood disorders
Ongoing growth of PCR-based CDx tests
Up to five FDA submissions and / or launches
planned for CDx tests
Strong pipeline expansion and additional
NGS-based immuno-oncology CDx collaborations
Sample to Insight
QIAsymphony
Investor presentation Q1 2018 24
QIAsymphony: Gold standard in molecular testing for Molecular Diagnostics and Life Science customers
2017 highlights
2018 catalysts
Significantly exceeded 2,000 cumulative placements
Successful regionalization strategy
(22 CE-IVD tests, 5 FDA-cleared assays)
Very positive customer response to new
liquid biopsy automation protocols
New front-end solution for GeneReader NGS System
Goal for more than 2,300 cumulative total placements
Continued double-digit CER consumables growth
Expand sample processing apps and test menu
Sample to Insight
Differentiated Technologies
Investor presentation Q1 2018 25
Proven ability to integrate cutting-edge breakthroughs into Sample to Insight workflows
Strengthening No. 1 leadership position in
liquid biopsy sample processing
~75% market share in microbiome sample
processing, full integrated POWER kits
Absolute leadership in Epigenetics
Exiqon long-read RNA applications
New microRNA applications for use with NGS
Double-digit CER growth
New, market-leading positions in emerging areas
New applications with Sample to Insight workflows
enhanced by QIAGEN bioinformatics
2017 highlights
2018 catalysts
Sample to Insight
STAT-Dx acquisition and QIAstat-Dx
26
Access to novel multiplex platform
Next generation of molecular multiplex syndromic testing technology
Drive dissemination of molecular testing
QIAstat-Dx:
Preparing for CE-IVD launch in H2 2018, U.S. in 2019
Two initial panels: respiratory and gastrointestinal
Plans to develop meningitis, blood culture, pneumonia,
transplant, oncology and immunoassay panels
Includes QIAGEN chemistries – technology and assay synergies
Significant channel and menu synergies with current QIAGEN portfolio
Key advantages:
Powerful processing capabilities for many sample types
Flexible approach to customize result reporting
Highly cost-efficient system fully connected to laboratory info systems
Only multiplex, syndromic system with real-time PCR and quantitative results
Multi-analyte capabilities, plans to launch immunoassay tests and expand into oncology
Leverage QIAGEN’s advantages in sample technologies, infectious diseases and global reach
(1) Acquisition to be funded from existing cash reserves and planned closing in second quarter of 2018. QIAGEN expects full-year 2018 sales of about $7 million and at least $30 million in 2019.
Due to investments, expected to be dilutive to full-year 2018 adjusted EPS by about $0.05 per share, but neutral in 2019.
Investor presentation Q1 2018
Launch of QIAstat-Dx subject to successful closing of acquisition
Sample to Insight
STAT-Dx acquisition and QIAstat-Dx
27
Novel one-step solution with expanded range of sample types and PCR-based test options
QIAstat-Dx
Sample to Insight One-step diagnostic solution
Broad menu Two syndromic assays at launch, other tests in development
Ease of use 1-minute hands-on time
Versatility Sample input flexibility to process swabs and complex samples
Speed Turnaround time of ~1 hour with full quantification
Reimbursement needs Flexibility in scaling target breadth and test results
Scalability Modular system (1-8 modules)
Connectivity Bi-directional HIS / LIS interface
Multi-analyte Immunoassay capabilities In development
HIS – Hospital information system LIS – Laboratory information system
✓
✓
✓
✓
✓
✓
✓
✓
Access to novel multiplex platform
Investor presentation Q1 2018
Launch of QIAstat-Dx subject to successful closing of acquisition
Sample to Insight
Agenda
28
Appendix
Portfolio review
Full-year 2017 results
Introducing QIAGEN
Investor presentation Q1 2018
Sample to Insight
Full-year 2017: Overview
Investor presentation Q1 2018 29
Key results
In $ millions (Except EPS) FY 2017 FY 2016 Change $ / (CER)
Net sales 1,417.5 1,338.0 +6% (+6%)
Adjusted net sales(1) 1,419.4 1,338.0 +6% (+6%)
Adj. net sales excluding
business portfolio changes(2) 1,394.3 1,302.2 +7% (+7%)
Operating income 153.4 98.8 NM
Adj. operating income(3) 371.5 324.7 +14%
Net (loss) income 40.4 80.4 NM
Adj. net income(3) 295.3 264.8 +12%
Diluted EPS(3) $0.17 $0.34
Adj. diluted EPS (CER)(3) $1.27
($1.27)$1.11
Achieved full-year 2017 targets with solid Q4 results
+7% CER adj. net sales growth excl. business portfolio change
vs. ~+7% CER outlook
$1.27 adjusted EPS ($1.27 CER) vs. $1.25-1.27 CER outlook
26% adjusted operating income margin vs. 24% in 2016
1
Sample to Insight portfolio momentum
Record year for QIAsymphony placements
QuantiFERON-TB sales with 24% growth, new DiaSorin partnership
Streamlined China business portfolio and positioned for faster growth
2
Full-year 2018 outlook and capital allocation
Adj. net sales growth CER target:(1)
Organic growth accelerates to ~6-7% CER vs. 5% CER in 2017
Adj. EPS target impacted by U.S. tax reform and STAT-Dx acquisition
New $200 million share repurchase program to be launched
4
Outlook – As of January 31, 2018
Q1 2018 FY 2018
Adj. net sales growth (CER)(1) +~5% +~6-7%
Adj. diluted EPS (CER)(3) ~$0.23-0.24 ~$1.31-1.33
STAT-Dx acquisition marks entry into multiplex syndromic testing
Highly synergistic acquisition to drive molecular testing dissemination
European launch of QIAstat-Dx planned for H2 2018, U.S. launch
in 2019 and menu expansion for infectious diseases and oncology
3
(1) Adjusted net sales include all revenue contributions from the January 2017 acquisition of bioinformatics company OmicSoft. Organic growth excludes business portfolio changes in both periods.
(2) Business portfolio changes include discontinuation of certain non-core PCR assays and the divestment of China HPV test R&D and commercial distribution to a local company.
(3) Adjusted figures exclude restructuring charges and other items detailed in reconciliation tables. Weighted number of diluted shares (FY 2017: 233.0 million, FY 2016: 239.0 million).
CER – Constant exchange rates NM – Not meaningful Results for net income and EPS based on income attributable to owners of QIAGEN N.V.
Sample to Insight
Q4 and FY 2017: Financial review
(In $ millions, unless indicated)(Diluted EPS in $ per share)
Fourth quarter Full-year
2017 2016 Change 2017 2016 Change
Net sales 396.9 366.5 8% (5% CER) 1,417.5 1,338.0 6% (6% CER)
Adjusted net sales(1) 397.1 366.5 8% (6% CER) 1,419.4 1,338.0 6% (6% CER)
Adj. net sales excluding business portfolio changes(2) 389.9 356.6 9% (6% CER) 1,394.3 1,302.2 7% (7% CER)
Gross profit margin 66% 62% 65% 63%
Adjusted gross profit margin 71% 71% 71% 71%
Operating income 43.4 4.2 NM 153.4 98.8 NM
Operating income margin 11% 1% 11% 7%
Adjusted operating income(3) 121.7 112.7 8% 371.5 324.7 14%
Adjusted operating income margin 31% 31% 26% 24%
Net (loss) income -39.7 8.6 NM 40.4 80.4 NM
Adjusted net income(3) 100.1 93.5 7% 295.3 264.8 12%
Tax rate NM NM NM NM
Adjusted tax rate 17% 15% 18% 16%
EPS ($ per share)(3) -$0.18 $0.04 $0.17 $0.34
Adjusted EPS (CER)(3) $0.43 ($0.43) $0.39 $1.27 ($1.27) $1.11
(1) Adjusted net sales include all revenue contributions from the January 2017 acquisition of bioinformatics company OmicSoft.
(2) Business portfolio changes include discontinuation of certain non-core PCR tests and the divestment of China HPV test R&D and commercial distribution to a local company.
(3) Adjusted figures exclude restructuring charges and other items detailed in reconciliation tables. Weighted number of diluted shares (Q4 2017: 231.8 million, Q4 2016: 239.6 million) (FY 2017: 233.0 million, FY 2016: 239.0 million)
Reported diluted EPS based on weighted number of basic shares (Q4 2017: 226.6 million).
CER – Constant exchange rates NM – Not meaningful Results for net income and EPS based on income attributable to owners of QIAGEN N.V.
Investor presentation Q1 2018 30
Sample to Insight
Q4 and FY 2017: Product type and customer class
(1) CDx co-development sales (Q4 2017: $18 million, +62% CER ) (FY 2017: $43 million, +34% CER); U.S. HPV sales (Q4 2017: $8 million, -22% CER, 2% of sales) (FY 2017: $28 million, -16% CER, 2% of sales)
Growth rates at CER (Constant exchange rates) Sales and sales contributions at actual FX rates Tables may contain rounding differences
Q4 2017 net sales: $396.9 million FY 2017 net sales: $1.418 billion
Q4 2017 adj. net sales: $397.1 million FY 2017 adj. net sales: $1.419 billion
Adj. Sales (In $ m) % CER change % of sales Adj. Sales (In $ m) % CER change % of sales
Consumables and related revenues $340 +6% 86% $1,245 +7% 88%
Instruments $57 +6% 14% $175 +1% 12%
Molecular Diagnostics(1) $193 +4% 49% $683 +6% 48%
Applied Testing $40 +9% 10% $137 +14% 10%
Pharma $72 +9% 18% $276 +7% 19%
Academia $92 +5% 23% $323 +4% 23%
Molecular Diagnostics Applied Testing Pharma Academia
Investor presentation Q1 2018 31
Q4 2017: Pharma and Applied Testing lead performance as all customer classes deliver growth
Q4 2017: +6% CER growth excl.
business portfolio change; single-digit
CER growth in consumables and flat
instrument sales; gains in Personalized
Healthcare and QIAsymphony
consumables
Q4 2017: Double-digit CER growth in
instruments and single-digit gains in
consumables; Americas lead regions
with strong double-digit CER growth
due to human ID / forensics business
expansion
Q4 2017: Robust double-digit CER
growth in consumables and related
revenues, but weaker instrument sales;
Americas deliver double-digit CER
growth complemented by EMEA and
Asia-Pacific / Japan regions
Q4 2017: Double-digit CER gains in
instruments and single-digit CER
growth in consumables; EMEA and
Asia-Pacific / Japan lead performance
across regions; customer sentiment
improving in U.S. and Europe
Sample to Insight
Q4 2017 net sales: $396.9 million FY 2017 net sales: $1.418 billion
Q4 2017 adj. net sales: $397.1 million FY 2017 adj. net sales: $1.419 billion
Adj. Sales (In $ m) % CER change% of sales
Adj. Sales (In $ m) % CER change % of sales
Americas(1) $176 +7% 44% $655 +4% 46%
Europe / Middle East / Africa $134 +6% 34% $463 +9% 33%
Asia-Pacific / Japan $86 +1% 22% $299 +7% 21%
Q4 and FY 2017: Geographic regions
(1) Americas excluding U.S. HPV Q4 2017 (+9% CER) and FY 2017 (+6% CER)
Top 7 EGM (Q4 2017: +9% CER / 18% of sales, FY 2017: +13% CER / 16% of sales); Rest of the world (Q4 2017 and FY 2017: Less than 1% of net sales)
Sales figures and sales contributions at actual FX rates Growth rates at CER Tables may contain rounding differences
Americas Europe / Middle East / Africa Asia-Pacific / Japan
Investor presentation Q1 2018 32
Q4 2017: High-single-digit CER growth in the U.S. and
Brazil more than offset double-digit CER decline in
Mexico due to tender expiry
Q4 2017: Germany, Italy and Turkey lead region to solid
performance, supported by gains in Nordic countries
Q4 2017: +5% CER growth excluding China business
portfolio changes, double-digit CER growth in India
along with single-digit CER gains in South Korea and
China, but weaker results in Japan
Q4 2017: Americas region leads performance, top 7 emerging markets grow +9% CER
Sample to Insight
FY 2017: Balance sheet and cash flow
Balance sheet data(As of December 31) 2017 2016
Group liquidity (In $ millions) 1,017 532
Net debt (In $ millions) 743 537
Shareholder equity ratio 50% 61%
Leverage ratio(1) 1.5x 1.2x
Cash flow (In $ millions) 2017 2016
Net cash provided by
operating activities(2) 286.8 341.6
Purchases of property,
plant and equipment-90.1 -74.5
Free cash flow(2) 196.7 267.1
(1) Leverage ratio is calculated on trailing four quarters as net debt / adjusted EBITDA
(2) 2017 results include cash payments for restructuring (Q4 2017: $7 million, FY 2017: $48 million) and litigation settlements (Q4 2017: $28 million, FY 2017: $41 million)
Leverage ratio(1)
FY 2017: Free cash flow of $197 million reduced by significant one-time cash payments
33Investor presentation Q1 2018
0.2
3.3
2.2
0.4
-0.1
0.90.9
1.11.3
1.61.2 1.5
2006 2008 2010 2012 2014 2016
2007 2009 2011 2013 2015 2017
Sample to Insight
In $ per shareLow
Change
vs. 2017High
Change
vs. 2017
Underlying adjusted EPS outlook $1.38 CER 9% $1.40 CER 10%
- Tax impact (higher adjusted tax rate vs. 2017) -$0.03 -$0.03
- 2018 acquisition: STAT-Dx (H2 2018 launch) -$0.05 -$0.05
+ New $200 million share repurchase program $0.01 $0.01
= 2018 adjusted EPS guidance (2017: $1.11) $1.31 CER 3% $1.33 CER 5%
Q1 and Full-year 2018: Outlook
Investor presentation Q1 2018 34
As of January 31, 2018
2018 outlook: Goals for strong organic sales growth and improvement in adjusted EPS
2018: Adjusted EPS outlook
Sales in $ millionsFull-year 2017 results Full-year 2018 assumptions
Organic growth in net sales(1) +5% CER +~6-7% CER
+ Divestment: Business portfolio changes $25 ~$7
+ 2017 acquisition contributions: Exiqon and OmicSoft $23
+ 2018 acquisition contributions: STAT-Dx (H2 2018 launch) ~$7
= Total 2018 adjusted net sales growth guidance $1,419.4 +~6-7% CER
(1) Organic growth excludes business portfolio changes in both years and acquisitions in first 12 months, also includes ~1.5 percentage points of headwind from U.S. HPV test sales (2017: $28 m, 2018 guidance: ~$10 m).
CER – Constant exchange rates
CER – Constant exchange rates
2018: Adjusted net sales outlook
Sample to Insight
Q1 2018 outlook Full-year 2018 outlook
Adjusted net sales(1) ~+5% CER ~+6-7% CER
Adjusted EPS(2)~$0.23-0.24 CER
(Prior year: $0.22)
~$1.31-1.33 CER
(Prior year: $1.27)
Adjustments to operating income (in $ millions):
Purchased intangibles amortization ~$25 m ~$100 m
Restructuring-related items ~$2 m ~$9 m
Business integration and acquisition-related items ~$5 m ~$16
Adjusted tax rate (In %) ~20-21% ~20-21%
Weighted average number of diluted shares outstanding
(Based on $33.00 share price for Q1 2018)~232 million ~232 million
Q1 and FY 2018: Outlook and assumptions
CER – Constant exchange rates
(1) Adjusted net sales include all revenue contributions from January 2017 acquisition of bioinformatics company OmicSoft. Due to purchase price accounting rules, reported net sales is reduced by fair value adjustments to
deferred revenues related to sales contracts executed prior to acquisition. 2018 adjusted net sales outlook includes sales from business portfolio changes in both periods.
(2) QIAGEN reports adjusted results, as well as results on a constant exchange rate (CER) basis, and other non-U.S. GAAP figures to provide additional insight into its performance. These results include adjusted net sales,
adjusted gross profit, adjusted operating income, adjusted net income attributable to owners of QIAGEN N.V. and adjusted diluted EPS. Adjusted results are non-GAAP financial measures that QIAGEN believes should be
considered in addition to reported results prepared in accordance with GAAP, but should not be considered as a substitute. QIAGEN believes certain items should be excluded from adjusted results when they are outside of
ongoing core operations, vary significantly from period to period, or affect the comparability of results with competitors and its own prior periods. Furthermore, QIAGEN uses non-GAAP and constant currency financial
measures internally in planning, forecasting and reporting, as well as to measure and compensate employees. QIAGEN also uses adjusted results when comparing current performance to historical operating results, which
have consistently been presented on an adjusted basis.
FY 2018 outlook includes planned sales of ~$7 million from anticipated H2 2018 launch of QIAstat-Dx system subject to acquisition of STAT-Dx, planned to be completed in second quarter of 2018.
Every $1.00 change in market price per share of common stock above $32.06 share price results in an increase / decrease of ~700,000 in dilutive shares due to call-spread overlay (CSO) related to 2019 and 2021 convertible
notes, while every $1.00 change above $50.97 share prices results in increase of ~600,000 in dilutive shares due to 2023 convertible notes.
As of January 31, 2018
35Investor presentation Q1 2018
Sample to Insight
Agenda
36
Appendix
Portfolio review
Full-year 2017 results
Introducing QIAGEN
Investor presentation Q1 2018
Sample to Insight
Global reach into the most attractive geographic markets
Investor presentation Q1 2018 37
ManchesterHilden
Germantown
Venlo
Shanghai
Shenzhen
Aarhus
Redwood City
Waltham
Germantown, Maryland
Americas
Hilden, Germany
Europe
Shanghai
Asia-Pacific
Sample to Insight
Executive Committee
Investor presentation Q1 2018 38
Exe
cu
tive
Co
mm
itte
eCEO
Peer Schatz
Bu
sin
ess
Deve
lop
ment(
1)
CFO
Roland Sackers
Business Development
Jean-Pascal Viola
Molecular Diagnostics
Thierry Bernard
Life Science
Thomas Schweins
Operations
Mark Gladwell
Commercial Operations
Manuel O. Méndez
BioinformaticsHuman Resources
Annette Koch Jonathan Sheldon
(1) Business Development is a strategic function reporting directly to CEO, but not included in EC.
Solid leadership team with experience and an effective structure
Sample to Insight
Employees as of December 31, 2017
AmericasEurope /
Middle East / Africa
Asia Pacific /
Japan / ROW
Total
Q4 2017
Total
Q4 2016Change
Production 279 679 123 1,081 996 9% (1)
R&D 218 691 44 953 995 -4%
Sales 592 718 575 1,885 1,909 -1%
Marketing 66 154 58 278 308 -10% (2)
Administration 90 325 76 491 476 3%
Total 1,245 2,567 876 4,688 4,684 0%
Investor presentation Q1 2018 39
(1) Increase in production due in part to insourcing of QuantiFERON manufacturing
(2) Decrease in marketing due in part to centralization of various marketing functions
Sample to Insight
Your contacts
Calendar
Q1 2018 results May 2018
Annual General Meeting June 2018
Q2 2018 results July 2018
Q3 2018 results October 2018
Share information
NYSE: QGEN
Frankfurt: QIA
ISIN / CUSIP: NL0012169213 / N72482 123
WKN: A2D KCH
Investor presentation Q1 2018 40
E-mail: ir@qiagen.com
Internet: ir.qiagen.com
www.linkedin.com/company/qiagen
www.facebook.com/QIAGEN
twitter.com/QIAGEN
www.youtube.com/user/QIAGENvideos
Download the QIAGEN IR App
John Gilardi
Vice President Corporate
Communications and IR
Phone: +49 2103 29 11711
Mobile: +49 152 018 11711
E-mail: john.gilardi@qiagen.com
Dr. Sarah Fakih
Associate Director
Investor Relations
Phone: +49 2103 29 11457
Mobile: +49 152 018 11457
E-mail: sarah.fakih@qiagen.com
Alexandra Koenig
Coordinator
Investor Relations
Phone: +49 2103 29 11709
Mobile: +49 152 018 11709
E-mail: alexandra.koenig@qiagen.com